Day One Biopharmaceuticals to Merge for $2.5 Billion at $21.50 Share Price
Day One Biopharmaceuticals agreed to be acquired by France-based Servier in a $2.5 billion deal valuing its shares at $21.50, a 68 percent premium to its closing price. Shares peaked at $21.23 intraday and closed 65.9 percent higher, marking a three-year high as the deal tracks toward a Q2 close.
1. Deal Structure and Valuation
Day One Biopharmaceuticals and Servier entered a definitive agreement for a $2.5 billion acquisition, with Servier offering $21.50 per share, reflecting a 68 percent premium to the company’s previous closing price and valuing the deal based on Day One’s clinical-stage oncology portfolio.
2. Stock Price Reaction
Following the merger news, Day One shares reached an intraday high of $21.23 before closing at $21.20, representing a 65.9 percent rise and marking the highest stock price in three years.
3. Expected Closing and Conditions
The transaction is expected to close in the second quarter, subject to customary regulatory approvals and shareholder consent, with both companies working to finalize conditions ahead of the scheduled timeline.
4. Strategic Rationale and Leadership Comments
Day One’s leadership highlighted Servier’s expertise in rare cancers and commitment to targeted therapies, noting the merger will extend their pediatric low-grade glioma program and preserve the patient-first approach that has defined the company.